We report the case of a patient affected by an extra-nodal non-Hodgkin lymphoma presenting as a unique, large retroperitoneal mass with an unusual clinical presentation mimicking gastric peptic or neoplastic disease. ...We report the case of a patient affected by an extra-nodal non-Hodgkin lymphoma presenting as a unique, large retroperitoneal mass with an unusual clinical presentation mimicking gastric peptic or neoplastic disease. The patientwas successfully treated with a first generation therapy,CHOP modified regimen (cyclophosphamide 600mg/m^2 intravenously on d 1, epirubicin 55mg/m^2 intravenously on d 1, vincristine 1.2 mg/m^2 intravenously on d 1,prednisone 60 mg/m^2 on d 1-5), and a complete response was achieved. The (18)F-fluorodeoxyglucose positron emission tomography was used to assess the therapy outcome. A brief review of literature is provided.展开更多
OBJECTIVE To observe the clinical efficacy and toxic effects of Mabthera （rituximab） in combination with the CHOP （R-CHOP） regimen for treating invasive B-cell non-Hodgkin＇s lymphoma. METHODS A total of 45 patien...OBJECTIVE To observe the clinical efficacy and toxic effects of Mabthera （rituximab） in combination with the CHOP （R-CHOP） regimen for treating invasive B-cell non-Hodgkin＇s lymphoma. METHODS A total of 45 patients with CD20 positive B-cell non- Hodgkin＇s lymphoma were randomly divided into the R-CHOP （22 cases） and CHOP groups （23 cases for controls）. They received the regimens of Mabthera in combination with CHOP or single CHOP therapy respectively. An appraisement of the curative effect could only be performed following 4 cycles of chemotherapy for the 45 patients. Follow-up was conducted to observe the conditions of survival. RESULTS The rate of complete remission （CR） in the R-CHOP group was 68.2%, with a total effective rate of 81.8%, and in the CHOP group these rates were 34.8% and 78.3% respectively. There was a significant difference in comparing the CR rates between the two groups （P 〈 0.05）. The 1, 2 and 3-year overall survival （OS） rates of the RCHOP group were 90.9%, 81.8% and 77.3%, respectively. In the CHOP group, the OS rates were respectively 91.3%, 69.5% and 47.8%. The difference in the 3-year OS between the two groups was significant （P 〈 0.05）. The toxic effects of the two groups were mainly a slight and moderate bone marrow depression and a gastrointesinal reaction, with similar tolerable toxic effects in the two groups （P 〉 0.05）. Adverse effects related to the Mabthera infusions occurred in 6 cases of the R-CHOP group （27.2%）. These effects lessened after symptomatic treatment. CONCLUSION The therapeutic regimen of Mabthera, in combination with CHOP （R-CHOP） has an obvious curative effect for treating invasive B-cell non-Hodgkin＇s lymphoma, with a favorable tolerance. It is highly recommended as the treatment of choice.展开更多
Objective:To observe the clinical efficacy of point application with De Huang(Rhizome Rhei Crude)powder at Shenque(CV 8)plus moxa-salt hot compress on the umbilicus for preventing gastrointestinal adverse reactions af...Objective:To observe the clinical efficacy of point application with De Huang(Rhizome Rhei Crude)powder at Shenque(CV 8)plus moxa-salt hot compress on the umbilicus for preventing gastrointestinal adverse reactions after chemotherapy for non-Hodgkin lymphoma(NHL).Methods:A total of 60 cases with NHL under chemotherapy were divided into two groups by hospitalization order,with 30 cases in each group.The control group was treated with routine nursing and the observation group was additionally given point application with Da Hueng(Rhizome Rhei Crude)powder plus moxa-salt hot compress on the umbilicus,to compare the effect in preventing gastrointestinal adverse reactions after chemotherapy between the two groups.Results:The occurrence rates of constipation,nausea,vomiting and poor appetite on the second day and fifth day after chemotherapy were obviously lower in the observation group than those in the control group,with statistically significant differences between the two groups(all P〈0.05).Conclusion;The point application with De Hueng(Rhizome Rhei Crude)powder at Shenque(CV 8)plus maxa-salt hot compress on the umbilicus can produce more significant efficacy in preventing the gastrointestinal adverse reactions after chemotherapy for NHL than routine nursing.Moreover,it is simple and easy to be used and popularized.展开更多
文摘We report the case of a patient affected by an extra-nodal non-Hodgkin lymphoma presenting as a unique, large retroperitoneal mass with an unusual clinical presentation mimicking gastric peptic or neoplastic disease. The patientwas successfully treated with a first generation therapy,CHOP modified regimen (cyclophosphamide 600mg/m^2 intravenously on d 1, epirubicin 55mg/m^2 intravenously on d 1, vincristine 1.2 mg/m^2 intravenously on d 1,prednisone 60 mg/m^2 on d 1-5), and a complete response was achieved. The (18)F-fluorodeoxyglucose positron emission tomography was used to assess the therapy outcome. A brief review of literature is provided.
文摘OBJECTIVE To observe the clinical efficacy and toxic effects of Mabthera （rituximab） in combination with the CHOP （R-CHOP） regimen for treating invasive B-cell non-Hodgkin＇s lymphoma. METHODS A total of 45 patients with CD20 positive B-cell non- Hodgkin＇s lymphoma were randomly divided into the R-CHOP （22 cases） and CHOP groups （23 cases for controls）. They received the regimens of Mabthera in combination with CHOP or single CHOP therapy respectively. An appraisement of the curative effect could only be performed following 4 cycles of chemotherapy for the 45 patients. Follow-up was conducted to observe the conditions of survival. RESULTS The rate of complete remission （CR） in the R-CHOP group was 68.2%, with a total effective rate of 81.8%, and in the CHOP group these rates were 34.8% and 78.3% respectively. There was a significant difference in comparing the CR rates between the two groups （P 〈 0.05）. The 1, 2 and 3-year overall survival （OS） rates of the RCHOP group were 90.9%, 81.8% and 77.3%, respectively. In the CHOP group, the OS rates were respectively 91.3%, 69.5% and 47.8%. The difference in the 3-year OS between the two groups was significant （P 〈 0.05）. The toxic effects of the two groups were mainly a slight and moderate bone marrow depression and a gastrointesinal reaction, with similar tolerable toxic effects in the two groups （P 〉 0.05）. Adverse effects related to the Mabthera infusions occurred in 6 cases of the R-CHOP group （27.2%）. These effects lessened after symptomatic treatment. CONCLUSION The therapeutic regimen of Mabthera, in combination with CHOP （R-CHOP） has an obvious curative effect for treating invasive B-cell non-Hodgkin＇s lymphoma, with a favorable tolerance. It is highly recommended as the treatment of choice.
文摘Objective:To observe the clinical efficacy of point application with De Huang(Rhizome Rhei Crude)powder at Shenque(CV 8)plus moxa-salt hot compress on the umbilicus for preventing gastrointestinal adverse reactions after chemotherapy for non-Hodgkin lymphoma(NHL).Methods:A total of 60 cases with NHL under chemotherapy were divided into two groups by hospitalization order,with 30 cases in each group.The control group was treated with routine nursing and the observation group was additionally given point application with Da Hueng(Rhizome Rhei Crude)powder plus moxa-salt hot compress on the umbilicus,to compare the effect in preventing gastrointestinal adverse reactions after chemotherapy between the two groups.Results:The occurrence rates of constipation,nausea,vomiting and poor appetite on the second day and fifth day after chemotherapy were obviously lower in the observation group than those in the control group,with statistically significant differences between the two groups(all P〈0.05).Conclusion;The point application with De Hueng(Rhizome Rhei Crude)powder at Shenque(CV 8)plus maxa-salt hot compress on the umbilicus can produce more significant efficacy in preventing the gastrointestinal adverse reactions after chemotherapy for NHL than routine nursing.Moreover,it is simple and easy to be used and popularized.
